FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/08/2026
Voltar para busca
Dado oficial do USPTO
PP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
12/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 35
Data de depósito
02/04/2025
Data de registro
12/05/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/05/2026
Última transação
12/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
16
Localização do titular
DE
Examinador
FOX III, LYAL L
Unidade examinadora
M40
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized lettering "PP" where the first "P" is backwards and there is a shaded square between the letters.
Titulares e representantes
Titulares
Paion Pharma GmbH
Representantes
Leigh Ann Lindquist Sughrue Mion, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalsbiological preparationsbiochemical preparations for use in industry and science; Chemicals for use in biotechnological manufacturing processes
Classe 5
Chemical and biochemical preparations for pharmaceutical or medical purposes for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunctionpain; Biological reagents for medical purposes; Biologics in the nature of pharmaceutical preparations for the treatment of for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunctionpain; Biochemical reagents for medical purposes; Diagnostic preparations for medical purposes; Reagents for medical purposes; Vaccines; Pharmaceutical preparations for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunctionpain; Sedatives; Anaesthetics; Hypnotics; Anxiolytics; Muscle relaxants; Anticonvulsants; Analgesics; Antibiotic preparations; Antiparasitics; Antihypertensives; Antihypotensives; Pharmaceutical preparationsimmunostimulants; Pharmaceutical preparations for gene therapy for the treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunctionpain
Classe 35
Wholesale store servicesretail store servicesmail order servicesonline wholesale store servicesonline retail store services featuring chemicalbiologicalbiochemical preparations for industrialscientificmedicalveterinary and pharmaceutical purposesalso featuring diagnostic preparations for medical purposesreagents for medical purposesvaccinespharmaceutical preparationspharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/05/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
12/05/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/03/2026
PUBO
PUBLISHED FOR OPPOSITION
24/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/03/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/02/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
27/02/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/02/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
27/02/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/02/2026
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/01/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/01/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/01/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/01/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/01/2026
RFNT
REFUSAL PROCESSED BY IB
07/11/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/10/2025
RFRR
REFUSAL PROCESSED BY MPU
17/10/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/09/2025
CNRT
NON-FINAL ACTION WRITTEN
02/09/2025
DOCK
ASSIGNED TO EXAMINER
29/08/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/07/2025
MAFR
APPLICATION FILING RECEIPT MAILED
06/06/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/06/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.